ATAI — ATAI Life Sciences BV
NASDAQ · Healthcare · Biotechnology
$7.34
+$0.00 (+0.07%)
ATAI Life Sciences BV (ATAI) is a biotechnology company listed on NASDAQ. It is led by Srinivas G. Rao M.D., Ph.D., based in Wallstraße 16, Berlin, Germany, 10179, with about 54 employees. Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Latest reported ATAI revenue for 2025-09-30 was $749.0K. Net income was -$61.1M. Revenue was up 4.2% from 2025-06-30 to 2025-09-30. ATAI currently screens at market cap $555.8M.
Use this ATAI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ATAI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ATAI SEC filings page. Lician reads the product cache first so this HTML stays unique to ATAI Life Sciences BV even when a live quote feed is slow.
About ATAI Life Sciences BV
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
ATAI Key Statistics
Market Cap
$555.82M
Volume
9.68M
Previous Close
$7.38
Day Range
$7.35 – $7.44
EPS
-$0.93
Revenue
$308.00K
Net Income
-$150.05M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-1.9%
Profit Margin
-48717.2%
Employees
54
ATAI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $308.00K | $314.00K | $233.00K | $20.38M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$150.05M | -$43.90M | -$157.42M | -$174.24M |
| EPS (Diluted) | -$0.93 | -$0.25 | -$0.98 | -$1.21 |
Total Assets
$159.39M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$17.50M
Operating Cash Flow
-$82.44M
Free Cash Flow
$0.00
ATAI Life Sciences BV Company Information
- Co-Founder & CEO
- Srinivas G. Rao M.D., Ph.D.
- Headquarters
- Wallstraße 16, Berlin, Germany, 10179
- Website
- atai.com
- Phone
- 49 89 2153 9035
- IPO / Founded
- 2021-06-18
- Sector
- Healthcare
- Industry
- Biotechnology